Presently genome analytical methods for application in ophthalmology are being further developed 57 58.Disclosure StatementThe author denies any conflict of interest that influences or biases his work.References 1 Friedrich B Heitz U Kroemer K Bieber T Dietel M Ertl G Gethmann CF Hallek M Hecker M Joerden JC Koller K Lengauer T Loffler M Lohse MJ Oberender P Propping P Puhler A Stingl G Taupitz J Zenner HP Indi- vidualized medicine.

Science 20073161039- 1043.Sos ML Koker M Weir BA Heynck S Rabinovsky R Zander T Seeger JM Weiss J Fischer F Frommolt P Michel K Peifer M Mermel C Girard L Peyton M Gazdar AF Minna JD Garraway LA Kashkar H Pao W Meyerson M Thomas RK PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

2 Su F Viros A Milagre C Trunzer K Bollag G Spleiss O Reis-Filho JS Kong X Koya RC Flaherty KT Chapman PB Kim MJ Hayward R Martin M Yang H Wang Q Hilton H Hang JS Noe J Lambros M Geyer F Dhomen N Niculescu-Duvaz I Zambon A Niculescu-Duvaz D Preece N Robert L Otte NJ Mok S Kee D Ma Y Zhang C Habets G Burton EA Wong B Nguyen H Kockx M Andries L Lestini B Nolop KB Lee RJ Joe AK Troy JL Gonzalez R Hutson TE Puzanov I Chmielowski B Springer CJ McArthur GA Sosman JA Lo RS Ribas A Marais R RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Nat Rev Cancer 20077169-181.Maemondo M Inoue A Kobayashi K Sugawara S Oizumi S Isobe H Gemma A Harada M Yoshizawa H Kinoshita I Fujita Y Okinaga S Hirano H Yoshimori K Harada T Ogura T Ando M Miyazawa H Tanaka T Saijo Y Hagiwara K Morita S Nukiwa T Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

N Engl J Med 2009361947-957.Rosell R Moran T Queralt C Porta R Cardenal F Camps C Majem M Lopez-Vivanco G Isla D Provencio M Insa A Massuti B Gonzalez-Larriba JL Paz-Ares L Bover I Garcia-Campelo R Moreno MA Catot S Rolfo C Reguart N Palmero R Sanchez JM Bastus R Mayo C Bertran-Alamillo J Molina MA Sanchez JJ Taron M Screening for epidermal growth factor receptor mutations in lung cancer.

N Engl J Med 20113642507-2516.Shepherd FA Rodrigues PJ Ciuleanu T Tan EH Hirsh V Thongprasert S Campos D Maoleekoonpiroj S Smylie M Martins R van KM Dediu M Findlay B Tu D Johnston D Bezjak A Clark G Santabarbara P Seymour L Erlotinib in previously treated non-small-cell lung cancer.

N Engl J Med 2009361958-967.Tsao MS Sakurada A Cutz JC Zhu CQ Kamel-Reid S Squire J Lorimer I Zhang T Liu N Daneshmand M Marrano P da Cunha SG Lagarde A Richardson F Seymour L Whitehead M Ding K Pater J Shepherd FA Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Hear Res 2012288 67-76.Zak M Pfister M Blin N The otoferlin interactome in neurosensory hair cells significance for synaptic vesicle release and trans-Golgi network review.

As a result treatment costs may be reduced because the expensive treatment may be restricted to the biomarker-selected patients.

Absence of KCNQ4 may result in deafness and thus DFNA3 gene analysis may contribute to an early indication of pediatric cochlear implantation 42.

